Roche: lung cancer drug reduces risk of death
(CercleFinance.com) - Roche said on Monday that its oral cancer drug Alecensa reduced the risk of disease worsening or death in Asian patients with a specific type of non-small cell lung cancer.
A phase III study showed that Alecensa cut the risk of disease worsening or death by 78%, compared to Pfizer's crizotinib, when given to Asian patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC).
The phase III study also demonstrated that, compared to crizotinib, Alecensa reduced the risk of disease progression in the central nervous system by 86%, Roche said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
A phase III study showed that Alecensa cut the risk of disease worsening or death by 78%, compared to Pfizer's crizotinib, when given to Asian patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC).
The phase III study also demonstrated that, compared to crizotinib, Alecensa reduced the risk of disease progression in the central nervous system by 86%, Roche said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.